AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25675797
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding (EOF) after general anesthesia (n=48)
Trial: 25675797
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral feeding (ROF) after regional anesthesia (n=47)
Trial: 25675797
Drug: Routine oral
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oral feeding (ROF) after general anesthesia (n=48)
Trial: 18191416
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (monotherapy)
Trial: 15679698
Drug: Subcutaneous sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous sumatriptan 6 mg (suma-sc)
Trial: 12091866
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) once per week for 6 weeks + 6 sessions of cognitive-behavioral treatment
Trial: 12091866
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) 3 times per week for 6 weeks + 6 sessions of cognitive-behavioral treatment
Trial: 9816048
Drug: Carboxyamido-triazole (CAI)
RxNorm normalized name: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboxyamido-triazole (CAI) liquid formulation at doses of 100, 125, and 150 mg/m2/day and 200 and 330 mg/m2 every other day
Trial: 9816048
Drug: Carboxyamido-triazole (CAI)
RxNorm normalized name: 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboxyamido-triazole (CAI) gelcap formulation at doses of 100 and 125 mg/m2/day and 200 mg/m2 every other day
Trial: 1675316
Drug: Propranolol (20-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (20-160 mg twice daily)
Trial: 7449302
Drug: Propranolol (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (average daily dose 240 mg)
Trial: 18620344
Drug: Right lateral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Right lateral position (RLP) after swallowing the capsule
Trial: 11461943
Drug: L-NAME +
RxNorm normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME + Placebo (PL)
Trial: 11461943
Drug: L-NAME +
RxNorm normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME + Losartan (LOS)
Trial: 11461943
Drug: L-NAME +
RxNorm normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME + Indomethacin (IND)
Trial: 11461943
Drug: L-NAME +
RxNorm normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NAME + Indomethacin + Losartan (IND + LOS)
Trial: 7978092
Drug: Ethanol 0.9
RxNorm normalized name: ethanol 0.9 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol 0.9 g/kg
Trial: 7978092
Drug: Control (Ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Ethanol 0.0 g/kg)
Trial: 29175569
Drug: Low-dose tranexamic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose tranexamic acid (10 mg/kg loading dose, then 1 mg·kg‐1·hr‐1 throughout surgery)
Trial: 26160625
Drug: Twice-daily administration
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily administration of perindopril (4 mg morning and 4 mg evening)
Trial: 26160625
Drug: Twice-daily administration
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily administration of losartan (50 mg morning and 50 mg evening)
Trial: 26160625
Drug: Once-daily evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily evening administration of perindopril (8 mg)
Trial: 26160625
Drug: Once-daily evening
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily evening administration of losartan (100 mg)
Trial: 23293945
Drug: Benzathine penicillin
RxNorm normalized name: Benzathine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzathine penicillin G (generic formulation, 1,200,000 IU)
Trial: 10683714
Drug: 1% solution
RxNorm normalized name: GUMSOL 5%-0.01% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% solution of Citrus limon and Cydonia oblongata
Trial: 10683714
Drug: 3% solution
RxNorm normalized name: Proxacol 3% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% solution of Citrus limon and Cydonia oblongata
Trial: 8973432
Drug: Solar treatment
RxNorm normalized name: Bos taurus solar plexus preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solar treatment (water left in full sunlight)
Trial: 1317657
Drug: L (Group
RxNorm normalized name: Meningococcal (Groups A,B,C,Y and W-135) Polysaccharide Vaccine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L (Group BII)
Trial: 30871628
Drug: Rituximab (induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (induction therapy)
Trial: 24692301
Drug: Triple DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple DMARD therapy + IM glucocorticoids
Trial: 24692301
Drug: Triple DMARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple DMARD therapy + oral glucocorticoids
Trial: 24692301
Drug: HCQ treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCQ treatment
Trial: 22974280
Drug: Linagliptin 5
RxNorm normalized name: linagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linagliptin 5 mg once daily for 18 weeks
Trial: 22974280
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 18 weeks, then glimepiride 1-4 mg once daily for 34 weeks
Trial: 9394942
Drug: Naltrexone, 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone, 1.0 mg/kg, daily
Trial: 199128
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of naloxone
Trial: 29306609
Drug: MED2005 (0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MED2005 (0.2% glyceryl trinitrate topical gel)
Trial: 26439240
Drug: Clonidine 0.3
RxNorm normalized name: CLONIDINE 0.3MG/24HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.3 mg (oral single dose)
Trial: 22534709
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg qd)
Trial: 12540331
Drug: Daily hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily hypertonic saline nasal irrigation for 6 months
Trial: 9824407
Drug: Capsaicin spray
RxNorm normalized name: capsaicin Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsaicin spray solution delivering 0.15 mg of capsaicin per nostril once every second or third day for a total of seven treatments.
Trial: 8109551
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of benazepril
Trial: 8109551
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of benazepril
Trial: 2681393
Drug: Mebendazole 200
RxNorm normalized name: mebendazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebendazole 200 mg
Trial: 2681393
Drug: Pyrantel 10
RxNorm normalized name: pyrantel 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrantel 10 mg/kg
Trial: 25880822
Drug: Skin-to-skin contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin-to-skin contact for 60 minutes, twice a day for 7 days
Trial: 21430518
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume ventilation (6 ml/kg)
Trial: 21430518
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (10 ml/kg tidal volume)
Trial: 15501201
Drug: 1.5 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g/d of glucosamine (n = 101)
Trial: 10831989
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (100 microgram)
Trial: 9180103
Drug: E6010 (0.22
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E6010 (0.22 mg/kg body weight intravenously over 2 min)
Trial: 9180103
Drug: Native t-PA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Native t-PA (28.8 mg or 14.4 million IU, 10% over 1 to 2 min, remainder over 60 min)
Trial: 8267066
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of oral slow‐release isradipine twice a day
Trial: 8267066
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of methyldopa three times a day
Trial: 8267066
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of oral slow‐release isradipine twice a day
Trial: 8267066
Drug: Matched controls
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched controls without medication
Trial: 3749828
Drug: Lidocaine 1%
RxNorm normalized name: LIDOCAINE 1% LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1% (2 ml)
Trial: 3749828
Drug: Diclofenac (Voltaren)
RxNorm normalized name: diclofenac Topical Gel [Voltaren]
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac (Voltaren) (50 mg, 2 ml)
Trial: 28801938
Drug: Gabapentin 1500
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1500 mg/day
Trial: 8750483
Drug: Hormone Replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone Replacement Therapy (HRT) for at least one year
Trial: 27893032
Drug: Individual Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual Cognitive Processing Therapy (CPT) - 60-minute sessions, twice weekly for 6 weeks
Trial: 27893032
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Processing Therapy (CPT) - 90-minute sessions, twice weekly for 6 weeks
Trial: 17389458
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) therapy, mean dose 0.16±0.06 mg/day
Trial: 2001087
Drug: Propafenone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (300 mg three times daily in 19 patients, 300 mg twice daily in 3 patients, and 150 mg twice daily in 1 patient)
Trial: 6340806
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% eye drops after placebo or 80 mg propranolol
Trial: 6340806
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% eye drops after 160 mg propranolol
Trial: 6340806
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% eye drops after 120 mg propranolol
Trial: 30817752
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for child SepAD (TAFF or CC)
Trial: 11215748
Drug: Octreotide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (0.1 mg subcutaneously three times a day)
Trial: 11215748
Drug: Control (conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conservative treatment only)
Trial: 8628802
Drug: Smooth-walled implants
RxNorm normalized name: Derma-Smoothe FS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smooth-walled implants
Trial: 1728731
Drug: Early antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early antibiotics (2 to 24 hours before incision)
Trial: 6142643
Drug: diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam 10 mg in its commercially available form
Trial: 6142643
Drug: diazepam 10
RxNorm normalized name: diazepam 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diazepam 10 mg masked in opaque capsules
Trial: 6142643
Drug: hydroxyzine pamoate
RxNorm normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydroxyzine pamoate 50 mg in its commercially available form
Trial: 6142643
Drug: hydroxyzine pamoate
RxNorm normalized name: Hydroxyzine Pamoate
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydroxyzine pamoate 50 mg masked in opaque capsules
Trial: 6142643
Drug: previous drug
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: previous drug therapy
Trial: 15660075
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg po preoperatively and Dexamethasone 10 mg IV intraoperatively
Trial: 15660075
Drug: Rofecoxib 50
RxNorm normalized name: rofecoxib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 50 mg po preoperatively
Trial: 15660075
Drug: Placebo po
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo po preoperatively and Dexamethasone 10 mg IV intraoperatively
Trial: 10100362
Drug: Irrigating fluids
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigating fluids containing glycine, mannitol, and sorbitol infused at 0.75 ml/kg/min for 20 min
Trial: 2238575
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (IVIG) therapy
Trial: 17001071
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg) administered monthly for 3 months
Trial: 15253688
Drug: Alefacept (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept (12 weekly injections followed by 12 treatment-free weeks)
Trial: 30249211
Drug: Combination nivolumab/ipilimumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination nivolumab/ipilimumab
Trial: 30249211
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care neoadjuvant radiation therapy
Trial: 26147943
Drug: Evidence supported
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence supported smoking cessation therapy (including pharmacotherapy and behavioral support)
Trial: 21218747
Drug: Intravenous omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous omeprazole (initial dose of 80 mg, followed by 8 mg/h infusion)
Trial: 21218747
Drug: Intravenous ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ranitidine (100 mg bolus, followed by 100 mg boluses every 6 hours for 72 hours)
Trial: 18523394
Drug: Radiographic esophageal
RxNorm normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiographic esophageal imaging by oral administration of contrast media
Trial: 15926017
Drug: Amitriptyline 10
RxNorm normalized name: amitriptyline 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 10 mg daily for two months
Trial: 15926017
Drug: Intra-oral device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-oral device appliance for two months
Trial: 10340911
Drug: Terbinafine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine (250 mg once daily for 14 days)
Trial: 1775605
Drug: Arecoline at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arecoline at 4 mg/day
Trial: 399858
Drug: Salbutamol dry
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol dry powder (200 micrograms per capsule)
Trial: 399858
Drug: Rotahaler (device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotahaler (device for powder administration)
Trial: 19917927
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy followed by concurrent chemoradiotherapy (CRT)
Trial: 11277642
Drug: Carboplatin alone
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin alone (300 mg/m2 every 28 days for five cycles)
Trial: 11277642
Drug: Carboplatin plus
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin plus epidoxorubicin (120 mg/m2 and 300 mg/m2 every 28 days for five cycles)
Trial: 8371471
Drug: Beta-blockers (class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (class II agents)
Trial: 8371471
Drug: Amiodarone (class
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (class III agent)
Trial: 8371471
Drug: Class IV
RxNorm normalized name: Class IV antiarrhythmic agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Class IV agents (calcium channel blockers)
Trial: 9209898
Drug: Vaginal estriol
RxNorm normalized name: estriol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estriol (0.5 mg daily)
Trial: 9209898
Drug: 17 beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta‐estradiol (0.05 mg daily)
Trial: 8272550
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (CDP, 2 cycles) followed by radical surgery
Trial: 3040605
Drug: Enalapril (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5-10 mg twice daily)
Trial: 29302858
Drug: Eribulin mesilate
RxNorm normalized name: Eribulin mesilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin mesilate 1.4 mg/m2 intravenously on days 1 and 8
Trial: 29302858
Drug: Capecitabine 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 1.25 g/m2 orally twice daily on days 1-14 (21-day cycles)
Trial: 24584818
Drug: Spouse-assisted lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spouse-assisted lifestyle intervention (9 monthly telephone calls to patients and spouses)
Trial: 20507841
Drug: Diclofenac 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 3% gel treatment
Trial: 18826094
Drug: Sonographically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonographically guided percutaneous ethanol injection (4 injections on average in the first group, 6 injections in the second group, 2-10 ml ethanol per injection)
Trial: 18826094
Drug: Sonographically guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sonographically guided percutaneous ethanol injection (6 injections)
Trial: 15975536
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy with esomeprazole 20mg b.i.d., clarithromycin 500 mg b.i.d. and amoxycillin 1g b.i.d.
Trial: 15975536
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy comprising of the same regimen plus lactoferrin 200mg b.i.d.
Trial: 9249934
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (tacrolimus 0.10 mg/kg and prednisolone)
Trial: 9249934
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (tacrolimus 0.06 mg/kg, prednisolone, and azathioprine)
Trial: 8388030
Drug: Alpha-interferon preparations
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alpha-interferon preparations (exact dosage and duration not specified)
Trial: 28579233
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with 120μg RSV F protein and 0.4mg aluminum
Trial: 28579233
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 60μg RSV F protein and 0.8mg aluminum
Trial: 28579233
Drug: All formulations
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All formulations (including placebo)
Trial: 25647729
Drug: Nonoxynol-9 2%
RxNorm normalized name: NONOXYNOL-9 2% GEL,VAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoxynol-9 2% gel
Trial: 24127924
Drug: Hydrogen-rich water
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen-rich water (HRW) 1200-1800 mL/day, twice daily for 6 weeks